<p>TELA Bio（纳斯达克代码：TELA - 获取免费报告）预计将在 2026 年 5 月 12 日星期二市场收盘后发布其 2026 年第一季度财报。分析师预计该公司将宣布每股收益为（$0.14），季度收入为 1859.70 万美元。有兴趣的人士可以查看公司即将发布的 2026 年第一季度财报的信息，以获取关于定于 2026 年 5 月 12 日下午 4:30（东部时间）的电话会议的最新详情。</p>
<p>TELA Bio（纳斯达克代码：TELA - 获取免费报告）最近一次发布季度财报是在 3 月 24 日星期二。该公司报告的季度每股收益为（$0.16），超出分析师一致预期的（$0.18）$0.02。该季度的收入为 2087 万美元，而分析师预期为 2104 万美元。TELA Bio 的股本回报率为负 433.58%，净利润率为负 48.37%。平均而言，分析师预计 TELA Bio 在当前财年将发布每股收益为-$1，在下一个财年将发布每股收益为$0。</p>
<h2>TELA Bio 股票表现</h2>
<p>在周二的交易中，纳斯达克 TELA 上涨了$0.10，达到了$1.19。该公司的股票交易量为 332,411 股，而其平均交易量为 196,760 股。该公司的市值为 5324 万美元，市盈率为-1.43，贝塔值为 1.30。TELA Bio 的 52 周低点为$0.50，52 周高点为$2.20。该公司的速动比率为 3.59，流动比率为 4.20，债务与股本比率为 8.82。该公司的 50 日移动平均价格为$0.73，200 日移动平均价格为$0.98。</p>
<h2>分析师评级调整</h2>
<p>TELA 最近受到了一些分析师报告的关注。Piper Sandler 在 3 月 25 日星期三的报告中将 TELA Bio 的目标价从$1.25 下调至$1.00，并对该公司给予了 “中性” 评级。Weiss Ratings 在 4 月 21 日星期二的研究报告中重申了对 TELA Bio 股票的 “卖出（e+）” 评级。Canaccord Genuity Group 在 3 月 25 日星期三的研究报告中将 TELA Bio 的目标价从$4.00 下调至$2.00，并对该股票给予了 “买入” 评级。Citizens Jmp 在 3 月 27 日星期五的研究报告中将 TELA Bio 的目标价从$5.00 下调至$3.00，并对该公司给予了 “市场表现优于大盘” 的评级。最后，Lake Street Capital 在 3 月 25 日星期三的研究报告中将 TELA Bio 的目标价从$3.00 下调至$2.00，并对该公司给予了 “买入” 评级。三位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，共识目标价为$2.20。</p>
<p><strong>查看我们对 TELA 的最新分析</strong></p>
<h2>TELA Bio 的机构交易</h2>
<p>一些大型投资者最近增加或减少了对 TELA 的持股。Citadel Advisors LLC 在第三季度将其在 TELA Bio 的持股比例提高了 161.3%。Citadel Advisors LLC 现在拥有 35,281 股该公司的股票，价值 53,000 美元，此前在上个季度增持了 21,781 股。XTX Topco Ltd 在第四季度收购了 TELA Bio 的新股份，价值约 48,000 美元。Renaissance Technologies LLC 在第四季度将其在 TELA Bio 的持股比例提高了 101.4%。Renaissance Technologies LLC 现在拥有 128,700 股该公司的股票，价值 152,000 美元，此前在该期间增持了 64,800 股。最后，Susquehanna International Group LLP 在第三季度将其在 TELA Bio 的持股比例提高了 551.2%。Susquehanna International Group LLP 现在拥有 85,763 股该公司的股票，价值 128,000 美元，此前在上个季度增持了 72,594 股。机构投资者和对冲基金持有该公司 94.35% 的股票。</p>
<h2>TELA Bio 公司简介</h2>
<p>（获取免费报告）</p>
<p>TELA Bio, Inc（纳斯达克代码：TELA）是一家总部位于宾夕法尼亚州马尔文的商业阶段医疗技术公司。该公司专注于开发、制造和商业化再生医学和先进软组织修复解决方案。通过整合专有生物材料和加工技术，TELA Bio 旨在提供支持身体自然愈合过程的产品，用于伤口闭合、疝气修复、重建手术和其他外科专业。</p>
<p>该公司的产品组合包括无细胞真皮基质、止血剂和组织支架系统。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们认为比 TELA Bio 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVMQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVMQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 TELA Bio 吗？</h2>
<p>在你考虑 TELA Bio 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 TELA Bio 并不在名单上。</p>
<p>虽然 TELA Bio 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TELA

<p>TELA Bio（纳斯达克代码：TELA）计划于 5 月 12 日发布 2026 年第一季度财报，分析师预测每股亏损 0.14 美元，收入为 1860 万美元。该公司此前报告 2025 年第一季度每股亏损 0.16 美元，超出预期。TELA 的股票目前交易价格为 1.19 美元，市值为 5324 万美元。最近的分析师评级显示买入、持有和卖出的推荐混合，平均目标价格为 2.20 美元。机构投资者持有 TELA 94.35% 的股份，显示出对该公司的强烈兴趣</p>

<p>TELA Bio (NASDAQ:TELA - Get Free Report) is expected to issue its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $18.5970 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.</p>
<div class="lb-trans"><p>TELA Bio（纳斯达克代码：TELA - 获取免费报告）预计将在 2026 年 5 月 12 日星期二市场收盘后发布其 2026 年第一季度财报。分析师预计该公司将宣布每股收益为（$0.14），季度收入为 1859.70 万美元。有兴趣的人士可以查看公司即将发布的 2026 年第一季度财报的信息，以获取关于定于 2026 年 5 月 12 日下午 4:30（东部时间）的电话会议的最新详情。</p>
</div><p>TELA Bio (NASDAQ:TELA - Get Free Report) last posted its quarterly earnings data on Tuesday, March 24th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. The business had revenue of $20.87 million for the quarter, compared to analyst estimates of $21.04 million. TELA Bio had a negative return on equity of 433.58% and a negative net margin of 48.37%. On average, analysts expect TELA Bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>TELA Bio（纳斯达克代码：TELA - 获取免费报告）最近一次发布季度财报是在 3 月 24 日星期二。该公司报告的季度每股收益为（$0.16），超出分析师一致预期的（$0.18）$0.02。该季度的收入为 2087 万美元，而分析师预期为 2104 万美元。TELA Bio 的股本回报率为负 433.58%，净利润率为负 48.37%。平均而言，分析师预计 TELA Bio 在当前财年将发布每股收益为-$1，在下一个财年将发布每股收益为$0。</p>
</div><h2>TELA Bio Stock Performance</h2>
<div class="lb-trans"><h2>TELA Bio 股票表现</h2>
</div><p>NASDAQ TELA traded up $0.10 during trading on Tuesday, hitting $1.19. The company's stock had a trading volume of 332,411 shares, compared to its average volume of 196,760. The firm has a market cap of $53.24 million, a P/E ratio of -1.43 and a beta of 1.30. TELA Bio has a 52 week low of $0.50 and a 52 week high of $2.20. The company has a quick ratio of 3.59, a current ratio of 4.20 and a debt-to-equity ratio of 8.82. The firm has a 50 day moving average price of $0.73 and a 200 day moving average price of $0.98.</p>
<div class="lb-trans"><p>在周二的交易中，纳斯达克 TELA 上涨了$0.10，达到了$1.19。该公司的股票交易量为 332,411 股，而其平均交易量为 196,760 股。该公司的市值为 5324 万美元，市盈率为-1.43，贝塔值为 1.30。TELA Bio 的 52 周低点为$0.50，52 周高点为$2.20。该公司的速动比率为 3.59，流动比率为 4.20，债务与股本比率为 8.82。该公司的 50 日移动平均价格为$0.73，200 日移动平均价格为$0.98。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>TELA has been the subject of a number of recent analyst reports. Piper Sandler dropped their price target on TELA Bio from $1.25 to $1.00 and set a &#34;neutral&#34; rating for the company in a report on Wednesday, March 25th. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of TELA Bio in a research note on Tuesday, April 21st. Canaccord Genuity Group reduced their price target on shares of TELA Bio from $4.00 to $2.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, March 25th. Citizens Jmp lowered their price objective on shares of TELA Bio from $5.00 to $3.00 and set a &#34;market outperform&#34; rating for the company in a research report on Friday, March 27th. Finally, Lake Street Capital decreased their target price on TELA Bio from $3.00 to $2.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, March 25th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and a consensus target price of $2.20.</p>
<div class="lb-trans"><p>TELA 最近受到了一些分析师报告的关注。Piper Sandler 在 3 月 25 日星期三的报告中将 TELA Bio 的目标价从$1.25 下调至$1.00，并对该公司给予了 “中性” 评级。Weiss Ratings 在 4 月 21 日星期二的研究报告中重申了对 TELA Bio 股票的 “卖出（e+）” 评级。Canaccord Genuity Group 在 3 月 25 日星期三的研究报告中将 TELA Bio 的目标价从$4.00 下调至$2.00，并对该股票给予了 “买入” 评级。Citizens Jmp 在 3 月 27 日星期五的研究报告中将 TELA Bio 的目标价从$5.00 下调至$3.00，并对该公司给予了 “市场表现优于大盘” 的评级。最后，Lake Street Capital 在 3 月 25 日星期三的研究报告中将 TELA Bio 的目标价从$3.00 下调至$2.00，并对该公司给予了 “买入” 评级。三位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，共识目标价为$2.20。</p>
</div><p><strong>View Our Latest Analysis on TELA</strong></p>
<div class="lb-trans"><p><strong>查看我们对 TELA 的最新分析</strong></p>
</div><h2>Institutional Trading of TELA Bio</h2>
<div class="lb-trans"><h2>TELA Bio 的机构交易</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in TELA. Citadel Advisors LLC lifted its position in TELA Bio by 161.3% during the third quarter. Citadel Advisors LLC now owns 35,281 shares of the company's stock worth $53,000 after acquiring an additional 21,781 shares during the last quarter. XTX Topco Ltd acquired a new stake in TELA Bio during the 4th quarter worth approximately $48,000. Renaissance Technologies LLC boosted its stake in TELA Bio by 101.4% in the 4th quarter. Renaissance Technologies LLC now owns 128,700 shares of the company's stock valued at $152,000 after purchasing an additional 64,800 shares during the period. Finally, Susquehanna International Group LLP grew its holdings in TELA Bio by 551.2% in the 3rd quarter. Susquehanna International Group LLP now owns 85,763 shares of the company's stock valued at $128,000 after buying an additional 72,594 shares in the last quarter. Institutional investors and hedge funds own 94.35% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近增加或减少了对 TELA 的持股。Citadel Advisors LLC 在第三季度将其在 TELA Bio 的持股比例提高了 161.3%。Citadel Advisors LLC 现在拥有 35,281 股该公司的股票，价值 53,000 美元，此前在上个季度增持了 21,781 股。XTX Topco Ltd 在第四季度收购了 TELA Bio 的新股份，价值约 48,000 美元。Renaissance Technologies LLC 在第四季度将其在 TELA Bio 的持股比例提高了 101.4%。Renaissance Technologies LLC 现在拥有 128,700 股该公司的股票，价值 152,000 美元，此前在该期间增持了 64,800 股。最后，Susquehanna International Group LLP 在第三季度将其在 TELA Bio 的持股比例提高了 551.2%。Susquehanna International Group LLP 现在拥有 85,763 股该公司的股票，价值 128,000 美元，此前在上个季度增持了 72,594 股。机构投资者和对冲基金持有该公司 94.35% 的股票。</p>
</div><h2>TELA Bio Company Profile</h2>
<div class="lb-trans"><h2>TELA Bio 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>TELA Bio, Inc NASDAQ: TELA is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body's natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.</p>
<div class="lb-trans"><p>TELA Bio, Inc（纳斯达克代码：TELA）是一家总部位于宾夕法尼亚州马尔文的商业阶段医疗技术公司。该公司专注于开发、制造和商业化再生医学和先进软组织修复解决方案。通过整合专有生物材料和加工技术，TELA Bio 旨在提供支持身体自然愈合过程的产品，用于伤口闭合、疝气修复、重建手术和其他外科专业。</p>
</div><p>The company's product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.</p>
<div class="lb-trans"><p>该公司的产品组合包括无细胞真皮基质、止血剂和组织支架系统。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than TELA Bio</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 TELA Bio 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVMQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=TELA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in TELA Bio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 TELA Bio 吗？</h2>
</div><p>Before you consider TELA Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 TELA Bio 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TELA Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 TELA Bio 并不在名单上。</p>
</div><p>While TELA Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 TELA Bio 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

TELA Bio（TELA）预计将在周二发布财报